

**MORPHOLOGICAL FEATURES OF RAT KIDNEY ORGANOGENESIS DEVELOPING UNDER INFLUENCE OF ENALAPRIL AND NIFEDIPIN**

I.Yu. Akinshevich


**SUMMARY**

Organogenesis of rat metanephros from 15th for the 22th days of gestation from 112 «Vistar» female rats got in seven series of experiment were investigated. Control group metanephros and from females, getting the therapeutic, subtoxic and toxic dose of enalapril and nifedipin were studied. Enalapril changes metanephros organogenesis and conduces to their sharp excalation with diminishing of nephron number and primary defeat of the tubular system. The nifedipin reception results in insignificant deceleration of metanephros development and deformation of renal corpuscles. The least substantial morphological changes are in metanephros after the reception of enalapril in a therapeutic dose, and most substantial – after application of subtoxic dose. At a nifedipin reception morphological changes depends from the dose. They are most substantial after the reception of toxic dose and the least – after introduction of therapeutic dose.


112 «Vistar» female rats, 15- 22- days of gestation, were investigated. Control group metanephros and from females, getting the therapeutic, subtoxic and toxic dose of enalapril and nifedipin were studied. Enalapril changes metanephros organogenesis and conduces to their sharp excalation with diminishing of nephron number and primary defeat of the tubular system. The nifedipin reception results in insignificant deceleration of metanephros development and deformation of renal corpuscles. The least substantial morphological changes are in metanephros after the reception of enalapril in a therapeutic dose, and most substantial – after application of subtoxic dose. At a nifedipin reception morphological changes depends from the dose. They are most substantial after the reception of toxic dose and the least – after introduction of therapeutic dose.

[2]. 5% [11]. [5, 10]. [3, 12]. [6, 7].

« », 15- 22- . 15-  
 , ,  
 ,  
 ,  
 (86/609/ ), 16-  
 « » . 17-  
 c 5 . ( .1).  
 [1]. 18-  
 12- 22-  
 . 14-



.1.



17

- .1. ; -  
 , : .10, .10.  
 S-  
 20-  
 S-  
 17- 22-  
 ,  
 1- 18-

17-  
( . . 1). L-  
17- (NO), [8, 9].  
[4].  
20- 18-  
4  
20-  
22-  
22-  
17- 18-  
4- 22-  
S-  
20- 18- 20-  
22-

- 22-
1. 2006. – 289 .
  2. // - . – 2006. – 51, 2. – 18-23.
  3. Alexander B. T. Fetal programming of hypertension / B. T. Alexander // *Am J Physiol Regul Integr Comp Physiol.* – 2006. – V. 290, N 1. – P. R1-R10.
  4. Blea C.W. Effect of nifedipine on fetal and maternal hemodynamics and blood gases in the pregnant ewe / C.W. Blea, J.M. Barnard, R.R. Magness [et.al.] // *Am J Obstet Gynecol.* – 1997. – V. 176, 4 – P. 922-930.
  5. Chen N. Calcium channel blockers versus other classes of drugs for hypertension / N. Chen, M. Zhou, M. Yang // *Cochrane Database Syst Rev.* – 2010. – Vol. 4, N 8. – CD003654.
  6. Magee L.A. Treating hypertension in women of child-bearing age and during pregnancy / L.A. Magee // *Drug Sof.* – 2001. – Vol. 24, 6. – P. 457-474.
  7. Montan S. Drugs used in hypertensive diseases in pregnancy / S. Montan // *Curr Opin Obstet Gynecol.* – 2004. – Vol. 16, N 2. – P. 111-115.
  8. Queen L.R. Mechanisms underlying beta2-adrenoceptor-mediated nitric oxide generation by human umbilical vein endothelial cells / L.R. Queen, Y. Ji, B. Xu // *J Physiol.* – 2006. – Vol. 15, N 576, Pt 2. – P. 585-594.
  9. Sobrevia L. A role for insulin on L-arginine transport in fetal endothelial dysfunction in hyperglycaemia / L. Sobrevia, M. Gonzalez // *Curr Vasc Pharmacol.* – 2009. – Vol. 7, N 4. – P. 467-474.
  10. Tawara S. Progress of the study of rho-kinase and future perspective of the inhibitor / S. Tawara, H. Shimokawa // *Yakugaku Zasshi.* – 2007. – Vol. 127, N 3. – P. 501-514.
  11. Wright J.M. First-line drugs for hypertension / J.M. Wright, V.M. Musini // *Cochrane Database Syst Rev.* – 2009. – Vol. 8, N 3. – CD001841.
  12. Zandi-Nejad K. Adult hypertension and kidney disease: the role of fetal programming / K. Zandi-Nejad, V. A. Luyckx, B. M. Brenner // *Hypertension.* – 2006. – Vol. 47, N 3. – P. 502-508.